Basic therapy for Alzheimer’s disease: current trends

February 27, 2019
966
Resume

The article presents the key points of the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease — the main causer of the development of senile dementia. The main pathogenetic links of the disease are presented, the main methods of treatment, current trends in basic therapy using the most widely used drugs are considered.

Published: 27.02.2019

References:

  • Gavrilova S.I. (2003) Farmakoterapiya bolezni Altsgeymera. Puls, Moskva, 319 s.
  • Illarioshkin S.N. (2008) Rannyaya diagnostika neyrodegenerativnyih zabolevaniy. Nervyi, 1: 11–13.
  • Kompendium — lekarstvennyie preparatyi (2018) Memantin (Memantine) (https://compendium.com.ua/inn/77/342/memantine/).
  • Alzheimer Europe (2017) Dementia in Europe Yearbook 2017 (https://www.alzheimer-europe.org/Publications/Dementia-in-Europe-Yearbooks).
  • Alzheimer’s Association (2014) 2014 Alzheimer’s disease facts and figures. Alzheimers Dement., 10(2): e47–e92.
  • Alzheimer’s Association (2017) FDA-approved treatments for Alzheimer’s (https://www.alz.org/media/Documents/fda-approved-treatments-alzheimers-ts.pdf).
  • Alzheimer’s Disease International (2015) World Alzheimer Report 2015: The Global Impact of Dementia (https://www.alz.co.uk/research/world-report-2015).
  • Arce M.P., Rodríguez-Franco M.I., González-Muñoz G.C. et al. (2009) Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer’s disease. J. Med. Chem., 52(22): 7249–7257.
  • Areosa S.A., McShane R., Sherriff F. (2004) Memantine for dementia. Cochrane Database Syst. Rev., 4: CD003154.
  • Areosa S.A., Sherriff F., McShane R. (2005) Memantine for dementia. Cochrane Database Syst. Rev., 3: CD003154.
  • Atri A., Hendrix S.B., Pejović V. et al. (2015) Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res. Ther., 7(1): 28.
  • Atri A., Shaughnessy L.W., Locascio J.J., Growdon J.H. (2008) Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord., 22(3): 209–221.
  • Birks J., Harvey R.J. (2006) Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev., 1: CD001190.
  • Black S.E., Doody R., Li H. et al. (2007) Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology, 69(5): 459–469.
  • Bloom G.S. (2014) Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol., 71(4): 505–508.
  • Boinpally R., Chen L., Zukin S.R. et al. (2015) A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer’s disease: two phase I studies in healthy volunteers. Clin. Drug Investig., 35(7): 427–435.
  • Castro A., Martinez A. (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr. Pharm. Des., 12(33): 4377–4387.
  • Chan S.L., Lu C., Mattson M.P. (2000) Modification of cysteine proteases and AMPA receptor subunits by the lipid peroxidation product 4-hyroxynonenal: impact on neuronal apoptosis and necrosis. Neurobiol. Aging., 21(1): 17.
  • Chun W., Johnson G.V. (2007) The role of tau phosphorylation and cleavage in neuronal cell death. Front. Biosci., 12: 733–756.
  • Cowburn R., Hardy J., Roberts P., Briggs R. (1988) Presynaptic and postsynaptic glutamatergic function in Alzheimer’s disease. Neurosci. Lett., 86(1): 109–113.
  • Danysz W., Parsons C.G. (2012) Alzheimer’s disease, β-amyloid, glutamate, NMDA receptors and memantine — searching for the connections. Br. J. Pharmacol., 167(2): 324–352.
  • Deardorff W.J., Grossberg G.T. (2016) A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug Des. Devel. Ther., 10: 3267–3279.
  • European Medicines Agency (2018) Guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease (https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf).
  • Farlow M.R. (2005) The search for disease modification in moderate to severe Alzheimer disease. A critical review of current evidence. Neurology, 65(Suppl. 3): S25–S30.
  • Farrell M.E., Chen X., Rundle M.M. et al. (2018) Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology, 91(19): e1809–e1821.
  • Ferri C.P., Prince M., Brayne C. et al.; Alzheimer’s Disease International (2005) Global prevalence of dementia: a Delphi consensus study. Lancet, 366(9503): 2112–2117.
  • Galasko D. (2001) New approaches to diagnose and treat Alzheimer’s disease: a glimpse of the future. Clin. Geriatr. Med., 17(2): 393–410.
  • Gauthier S., Molinuevo J.L. (2013) Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement., 9(3): 326–331.
  • Hartmann S., Möbius H.J. (2003) Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. Clin. Psychopharmacol., 18: 81–85.
  • Hort J., O’Brien J.T., Gainotti G. et al.; EFNS Scientist Panel on Dementia (2010) EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur. J. Neurol., 17(10): 1236–1248.
  • Iqbal K., Alonso Adel C., Chen S. et al. (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim. Biophys. Acta., 1739(2–3): 198–210.
  • Jelic V., Darreh-Shori T. (2010) Donepezil: a review of pharmacological characteristics and role in the management of Alzheimer disease. Clin. Med. Ins. Ther., 2: 771–788.
  • Jelic V., Winblad B. (2016) Alzheimer disease. Donepezil and nursing home placement — benefits and costs. Nat. Rev. Neurol., 12(1): 11–13.
  • Krstic D., Knuesel I. (2013) The airbag problem — a potential culprit for bench-to-bedside translational efforts: relevance for Alzheimer’s disease. Acta Neuropathol. Commun., 1: 62.
  • Lopez O.L., Becker J.T., Wahed A.S. et al. (2009) Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry, 80(6): 600–607.
  • Möbius H.J. (1999) Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer. Dis. Assoc. Disord., 13(Suppl. 3): S172–S178.
  • NICE (2018) Dementia: assessment, management and support for people living with dementia and their carers (https://www.nice.org.uk/guidance/NG97).
  • Parsons C.G., Danysz W., Dekundy A., Pulte I. (2013) Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox Res., 24(3): 358–369.
  • Rogawski M.A. (2004) What is the rationale for new treatment strategies in Alzheimer’s disease? CNS Spectr., 9(7 Suppl. 5): 6–12.
  • Rountree S.D., Atri A., Lopez O.L., Doody R.S. (2013) Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement., 9(3): 338–345.
  • Schmidt R., Hofer E., Bouwman F.H. et al. (2015) EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur. J. Neurol., 22(6): 889–898.
  • Selkoe D.J. (2015) Alzheimer’s Disease. In: R.N. Rosenberg, J.M. Pascual (Eds.) Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease (Fifth Edition). Elsevier, p. 753–768.
  • Tariot P.N., Farlow M.R., Grossberg G.T. et al. (2004) Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. A randomized controlled trial. JAMA, 291: 317–324.
  • Touchon J., Lachaine J., Beauchemin C. et al. (2014) The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur. J. Health Econ., 15(8): 791–800.
  • Wenk G.L. (2003) Neuropathologic changes in Alzheimer’s disease. J. Clin. Psychiatry, 64 Suppl. 9: 7–10.
  • WHO (2012) Dementia: a public health priority (https://www.who.int/mental_health/publications/dementia_report_2012/en/).
  • Winblad B., Kilander L., Eriksson S. et al.; Severe Alzheimer’s Disease Study Group (2006) Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet, 367(9516): 1057–1065.
  • Zekry D., Hauw J.J., Gold G. (2002) Mixed dementia: epidemiology, diagnosis, and treatment. J. Am. Geriatr. Soc., 50(8): 1431–1438.